Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efficient optimization strategy for marginal hits active against abl tyrosine kinases.

Sergey E Tkachenko1, Ilya Okun, Konstantin V Balakin

  • 1Chemical Diversity Labs, Inc. 11558 Sorrento Valley Road, San Diego, CA 92121, USA.

Current Drug Discovery Technologies
|February 14, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-property relationships of benzyl-substituted urea-based ligands with Phe-Phe linker targeting prostate-specific membrane antigen labeled with gallium-68.

Bioorganic chemistry·2026
Same author

Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes.

Molecules (Basel, Switzerland)·2026
Same author

Novel Small Molecule GLP-1R Agonists Based on 1<i>H</i>-Benzo[<i>d</i>]imidazole-5-Carboxylic Acid Scaffold.

Molecules (Basel, Switzerland)·2026
Same author

A mild and atom-efficient four-component cascade strategy for the construction of biologically relevant 4-hydroxyquinolin-2(1<i>H</i>)-one derivatives.

Beilstein journal of organic chemistry·2026
Same author

Selectivity analysis of CDK2 inhibitors via molecular dynamics of CDK1 and CDK2.

Journal of molecular graphics & modelling·2026
Same author

"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).

Current medicinal chemistry·2025

This study presents a rational approach to optimize drug-like properties of kinase inhibitors. By integrating chemoinformatics and combinatorial synthesis, researchers improved hit compounds from high-throughput screening.

Area of Science:

  • Medicinal Chemistry
  • Chemoinformatics
  • Drug Discovery

Background:

  • High-throughput screening (HTS) of small molecules often yields hits with poor ADME/Tox properties and low intellectual property (IP) potential.
  • These limitations necessitate empirical optimization during lead development, which can be time-consuming and inefficient.

Purpose of the Study:

  • To describe a rational, chemoinformatics-driven strategy for optimizing hit compounds identified from a kinase-focused library against abl tyrosine kinase.
  • To address common challenges in early drug discovery, such as unfavorable pharmacokinetic properties and limited IP space.

Main Methods:

  • Utilized modern chemoinformatics techniques, including automated bioisosteric transformations of initial hit compounds.
  • Employed efficient solution-phase combinatorial synthesis for rapid analog generation.

Related Experiment Videos

  • Applied advanced knowledge-based library design principles to guide optimization efforts.

    • Main Results:

    • Demonstrated a systematic approach to enhance the drug-like properties of kinase inhibitor hits.
    • Successfully applied chemoinformatics and combinatorial synthesis to overcome typical hit-to-lead challenges.
    • Generated optimized compounds with improved potential for further development.

    Conclusions:

    • A rational, integrated approach combining chemoinformatics and synthesis can effectively optimize hit compounds from HTS.
    • This strategy accelerates the drug discovery process by proactively addressing ADME/Tox and IP concerns.
    • The described methods provide a valuable framework for hit-to-lead optimization in kinase inhibitor research.